| scholarly article | Q13442814 |
| P50 | author | Wilson S Colucci | Q46618620 |
| Nazareno Paolocci | Q42067397 | ||
| Carlo Gabriele Tocchetti | Q42661613 | ||
| P2093 | author name string | Eiki Takimoto | |
| David A Kass | |||
| Ramesh C Gupta | |||
| Hani N Sabbah | |||
| Richard S Tunin | |||
| Mengjun Wang | |||
| Reza Mazhari | |||
| Samantapudi Daya | |||
| Douglas Cowart | |||
| P2860 | cites work | Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study | Q44371716 |
| NO- activates soluble guanylate cyclase and Kv channels to vasodilate resistance arteries | Q44438485 | ||
| Calcitonin gene-related peptide in vivo positive inotropy is attributable to regional sympatho-stimulation and is blunted in congestive heart failure | Q45182847 | ||
| Spontaneous and inducible ventricular arrhythmias in a canine model of chronic heart failure: relation to haemodynamics and sympathoadrenergic activation | Q45214282 | ||
| Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure | Q46556129 | ||
| Acute heart failure patient profiles, management and in-hospital outcome: results of the Italian Registry on Heart Failure Outcome | Q47339351 | ||
| Phospholamban thiols play a central role in activation of the cardiac muscle sarcoplasmic reticulum calcium pump by nitroxyl. | Q52695418 | ||
| A canine model of chronic heart failure produced by multiple sequential coronary microembolizations | Q67898469 | ||
| Ventricular systolic assessment in patients with dilated cardiomyopathy by preload-adjusted maximal power. Validation and noninvasive application | Q72415144 | ||
| Nitroxyl increases force development in rat cardiac muscle | Q79855253 | ||
| Mechanism of aerobic decomposition of Angeli's salt (sodium trioxodinitrate) at physiological pH | Q81254793 | ||
| Nitroxyl (HNO): a novel redox signaling molecule | Q83383537 | ||
| Cardiac myosin activation: a potential therapeutic approach for systolic heart failure | Q30583292 | ||
| Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load | Q33743649 | ||
| Nitroxyl anion exerts redox-sensitive positive cardiac inotropy in vivo by calcitonin gene-related peptide signaling. | Q33943302 | ||
| The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. | Q34209536 | ||
| Nitroxyl improves cellular heart function by directly enhancing cardiac sarcoplasmic reticulum Ca2+ cycling | Q34586280 | ||
| Nitroxyl activates SERCA in cardiac myocytes via glutathiolation of cysteine 674. | Q34615204 | ||
| Nitroxyl enhances myocyte Ca2+ transients by exclusively targeting SR Ca2+-cycling | Q34671389 | ||
| The specificity of nitroxyl chemistry is unique among nitrogen oxides in biological systems. | Q34756677 | ||
| The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis | Q34776831 | ||
| Positive inotropic and lusitropic effects of HNO/NO − in failing hearts: Independence from β-adrenergic signaling | Q34983537 | ||
| Nitroxyl-mediated disulfide bond formation between cardiac myofilament cysteines enhances contractile function. | Q36314776 | ||
| S-nitrosylation: integrator of cardiovascular performance and oxygen delivery | Q36497166 | ||
| HNO enhances SERCA2a activity and cardiomyocyte function by promoting redox-dependent phospholamban oligomerization | Q37204272 | ||
| A role for nitroxyl (HNO) as an endothelium-derived relaxing and hyperpolarizing factor in resistance arteries. | Q37255292 | ||
| Cardiac inotropes: current agents and future directions | Q37851240 | ||
| Acute decompensated heart failure - treatments and challenges - . | Q37985383 | ||
| Structure and regulation of soluble guanylate cyclase | Q37992160 | ||
| Diuretics and ultrafiltration in acute decompensated heart failure. | Q38016994 | ||
| Update on the Management of Acute Decompensated Heart Failure | Q39258163 | ||
| The shy Angeli and his elusive creature: the HNO route to vasodilation | Q43123682 | ||
| Analysis of isovolumic relaxation in failing hearts by monoexponential time constants overestimates lusitropic change and load dependence: mechanisms and advantages of alternative logistic fit. | Q43207759 | ||
| Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). | Q43490989 | ||
| Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial | Q43930568 | ||
| Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure | Q44112800 | ||
| P433 | issue | 6 | |
| P921 | main subject | heart failure | Q181754 |
| P304 | page(s) | 1250-1258 | |
| P577 | publication date | 2013-10-09 | |
| P1433 | published in | Circulation: Heart Failure | Q2865806 |
| P1476 | title | Nitroxyl (HNO): A novel approach for the acute treatment of heart failure | |
| P478 | volume | 6 |
| Q64258422 | A Phase 1 Randomized Study of Single Intravenous Infusions of the Novel Nitroxyl Donor BMS-986231 in Healthy Volunteers |
| Q38693298 | A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction. |
| Q39310989 | A change of heart: oxidative stress in governing muscle function? |
| Q90375261 | Acute Enhancement of Cardiac Function by Phosphodiesterase Type 1 Inhibition |
| Q38959942 | Agents with vasodilator properties in acute heart failure |
| Q38573100 | Autonomic Dysregulation as a Therapeutic Target for Acute HF. |
| Q34304941 | Brain temperature and its fundamental properties: a review for clinical neuroscientists |
| Q47156125 | CXL-1020, a Novel Nitroxyl (HNO) Prodrug, Is More Effective than Milrinone in Models of Diastolic Dysfunction-A Cardiovascular Therapeutic: An Efficacy and Safety Study in the Rat. |
| Q35987513 | Dietary nitrate improves cardiac contractility via enhanced cellular Ca²⁺ signaling |
| Q35155257 | Emerging importance of oxidative stress in regulating striated muscle elasticity |
| Q88955948 | Extension of C. elegans lifespan using the ·NO-delivery dinitrosyl iron complexes |
| Q53241855 | From comorbidities to heart failure with preserved ejection fraction: a story of oxidative stress. |
| Q47573464 | Guidelines for translational research in heart failure |
| Q38882867 | Heart failure-potential new targets for therapy |
| Q92454801 | Hurdles to Cardioprotection in the Critically Ill |
| Q38208442 | Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus |
| Q50660284 | Integrating New Pharmacologic Agents into Heart Failure Care: Role of Heart Failure Practice Guidelines in Meeting This Challenge. |
| Q26774063 | Interaction of Hydrogen Sulfide with Nitric Oxide in the Cardiovascular System |
| Q59129621 | Intravenous Infusion of the Novel HNO Donor BMS-986231 Is Associated With Beneficial Inotropic, Lusitropic, and Vasodilatory Properties in 2 Canine Models of Heart Failure |
| Q47904506 | Meeting report of the 8th International Conference on cGMP "cGMP: generators, effectors, and therapeutic implications" at Bamberg, Germany, from June 23 to 25, 2017. |
| Q49501122 | Nitric oxide signalling in cardiovascular health and disease. |
| Q38224809 | Nitroxyl (HNO) for treatment of acute heart failure |
| Q34738088 | Nitroxyl (HNO) reacts with molecular oxygen and forms peroxynitrite at physiological pH. Biological Implications. |
| Q92177044 | Nitroxyl (HNO) targets phospholamban cysteines 41 and 46 to enhance cardiac function |
| Q88770243 | Nitroxyl donors for acute heart failure: promising newcomers |
| Q26765793 | Novel Perspectives in Redox Biology and Pathophysiology of Failing Myocytes: Modulation of the Intramyocardial Redox Milieu for Therapeutic Interventions-A Review Article from the Working Group of Cardiac Cell Biology, Italian Society of Cardiology |
| Q41565976 | Oxidant sensor in the cGMP-binding pocket of PKGIα regulates nitroxyl-mediated kinase activity. |
| Q26785525 | Pharmacology and Clinical Drug Candidates in Redox Medicine |
| Q39384340 | Rapid Photoactivated Generation of Nitroxyl (HNO) under Neutral pH Conditions. |
| Q92554255 | Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure |
| Q34892722 | Soluble guanylate cyclase is required for systemic vasodilation but not positive inotropy induced by nitroxyl in the mouse. |
| Q27024879 | Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology |
| Q38935734 | The chemical biology of HNO signaling |
| Q38827338 | Therapeutic Potential of Nitroxyl (HNO) Donors in the Management of Acute Decompensated Heart Failure |
| Q38567657 | Ularitide: a natriuretic peptide candidate for the treatment of acutely decompensated heart failure |
| Q38214097 | Vasodilators in Acute Heart Failure: Review of the Latest Studies |
Search more.